In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers:

The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness
Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential for cure
The importance of patient preparation and shared decision-making in treatment planning
The role of bridging therapy and the significance of managing disease burden prior to CAR T-cell infusion
An overview of acute and chronic side effects associated with CAR T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity
The critical coordination efforts behind the scenes to ensure seamless patient care

Join us as we explore how collaboration among healthcare professionals can enhance patient outcomes in the evolving landscape of multiple myeloma treatment.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and share your thoughts in the comments!

#MultipleMyeloma, #CARTtherapy, #BridgingTherapy, #HoldingTherapy, #OncologyBrothers

Multiple Myeloma CAR-T Management - Partners in Practice

Oncology Brothers: Practice-Changing Cancer Discussions

Multiple Myeloma CAR-T Management - Partners in Practice